Article
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
Hepatology (Baltimore, Md.) - 1 Aug 2012
Jacobson Ira M, Marcellin Patrick, Zeuzem Stefan, Sulkowski Mark S, Esteban Rafael, Poordad Fred, Bruno Savino, Burroughs Margaret H, Pedicone Lisa D, Boparai Navdeep, Deng Weiping, DiNubile Mark J, Gottesdiener Keith M, Brass Clifford A, Albrecht Janice K, Bronowicki Jean-Pierre
Abstract excerpt
UNLABELLED: In comparison with peginterferon/ribavirin alone, boceprevir with peginterferon/ribavirin significantly improves sustained virological response (SVR) rates in patients with chronic hepatitis C virus (HCV) genotype 1 infections, but treatment failure remains a significant problem. Using phase 3 trial databases, we sought to develop stopping rules for patients destined to fail boceprevir-based...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.